贝伐珠单抗联合厄洛替尼对比厄洛替尼单药治疗日本晚期EGFR突变非小细胞肺癌(NEJ026):总生存分析
NEJ026是一项开放标签、随机、多中心3期试验,纳入228例晚期EGFR突变NSCLC患者,比较贝伐珠单抗联合厄洛替尼与厄洛替尼单药的疗效。
要点
- 贝伐珠单抗联合厄洛替尼未改善EGFR突变NSCLC的总生存。
核心结论
- 在晚期EGFR突变非小细胞肺癌患者中,贝伐珠单抗联合厄洛替尼并未延长总生存。
研究设计与样本
- 开放标签、随机、多中心3期试验(NEJ026),在日本69家医院和医疗中心进行。
- 共纳入228例IIIB期、IV期或术后复发EGFR突变NSCLC患者,随机1:1接受贝伐珠单抗联合厄洛替尼或厄洛替尼单药治疗。
- 改良意向治疗人群包括各112例接受至少一剂研究药物且有疗效评估的患者。
关键数值与推荐
- 总生存分析采用改良意向治疗人群,数据截止2019年11月30日。
- 联合组方案:厄洛替尼150mg口服每日一次+贝伐珠单抗15mg/kg静脉每21天一次。
- 单药组方案:厄洛替尼150mg口服每日一次。
临床怎么用
- 对于EGFR突变晚期NSCLC,贝伐珠单抗联合厄洛替尼虽延长无进展生存,但未转化为总生存获益,临床决策需综合考量。
- 总生存未获益可能与后续治疗影响有关,需个体化评估联合治疗的必要性。
局限性
- 开放标签设计,患者和研究者均知晓治疗分配。
- 总生存数据截止时部分患者仍存活,中位OS不可估计。
- 事后治疗可能影响总生存结果,但原文未详细说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bevacizumab is a promising candidate for combination treatment with epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could improve outcomes for patients with metastatic EGFR-mutant non-small-cell lung cancer (NSCLC). We have previously shown in NEJ026, a phase 3 trial, that the combination of bevacizumab plus erlotinib significantly prolonged progression-free survival compared with erlotinib alone in these patients. In further analyses, we aimed to examine the effects of bevacizumab-erlotinib on overall survival, time from enrolment to progressive disease during second-line treatment or death, and quality of life. METHODS: This open-label, randomised, multicentre, phase 3 trial (NEJ026) was done in 69 hospitals and medical, community-based centres across Japan. Eligible patients had stage IIIB, stage IV, or postoperative recurrent, EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg point mutation) NSCLC, had not previously received systemic chemotherapy, and were randomly assigned (1:1) by a computer-generated randomisation sequence and minimisation to receive either 150 mg oral erlotinib once daily plus 15 mg/kg intravenous bevacizumab once every 21 days, or 150 mg oral erlotinib once daily, until disease progression or intolerable toxicity. Randomisation was stratified according to sex, smoking status, EGFR mutation subtype, and clinical disease stage. All participants, investigators, and study personnel (including those assessing outcomes) were unmasked to treatment allocation. We report the secondary outcomes of overall survival and quality of life (the period from enrolment to confirmation of a minimally important difference on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30), and the exploratory outcome of time from enrolment to progressive disease during second-line treatment or death. Overall survival and the exploratory outcome were analysed in the modified intention-to-treat population, which comprised all randomly assigned patients who received at least one dose of the study drug and had response evaluations. Quality of life was analysed in patients in the modified intention-to-treat population who had completed the quality of life questionnaires. The trial is registered with the University Hospital Medical Information Network Clinical Trials Registry, UMIN000017069, and the Japan Registry of Clinical Trials, jRCTs031180056, and is currently closed. FINDINGS: Between June 3, 2015, and Aug 31, 2016, 228 patients were enrolled. 112 patients who received bevacizumab-erlotinib and 112 who received erlotinib only were included in the modified intention-to-treat population. At data cutoff (Nov 30, 2019) and a median follow-up of 39·2 months (IQR 23·9-43·5), the median overall survival was 50·7 months (95% CI 37·3-not estimable [NE]) in the bevacizumab-erlotinib group and 46·2 months (38·2-NE) in the erlotinib-only group (hazard ratio [HR] 1·007, 95% CI 0·681-1·490; p=0·97). In analysis of the exploratory outcome, after a median follow-up of 23·9 months (IQR 14·2-39·1), the median time from enrolment to progressive disease during second-line treatment or death was 28·6 months (95% CI 22·1-35·9) in the bevacizumab-erlotinib group and 24·3 months (20·4-29·1) in the erlotinib-only group (HR 0·773, 95% CI 0·562-1·065). The median time between enrolment and confirmation of a minimally important difference on the EORTC QLQ-C30 was 6·0 months (95% CI 5·2-11·3) in the bevacizumab-erlotinib group and 8·3 months (5·7-13·9) in the erlotinib-only group (p=0·47). INTERPRETATION: The addition of bevacizumab to erlotinib did not prolong survival in patients with metastatic EGFR-mutant NSCLC, but both treatment groups had relatively long survival durations. Why the addition of bevacizumab to erlotinib did not affect overall survival is unclear, but it is possible that the beneficial effects of combination therapy were not seen because overall survival was influenced by treatment regimens used after disease progression. FUNDING: Chugai Pharmaceutical.
引用
- Kawashima Y, Fukuhara T, Saito H, et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2021. PMID: 34454653. doi:10.1016/S2213-2600(21)00166-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。